Skip to main content

Hineline Lawrence J.'s Form 4 filing

Intra-Cellular Therapies, Inc.ITCI · filed Mar 13, 2023

Accession no.
0001209191-23-018284
Filed
Mar 13, 2023
Trade date
Mar 9-13, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $925.2K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hineline Lawrence J.CIK 0001585697Officer (SVP of Finance CFO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 9, 2023Common StockAGrant or awardAcquired+15,663$0.00$015,663Direct
Mar 10, 2023Common StockSSaleDisposed−12,963$43.17F3−$559,612.712,700Direct
Mar 10, 2023Common StockSSaleDisposed−2,700$42.52F4−$114,8040Direct
Mar 10, 2023Common StockMOption exerciseAcquired+5,582–F5–5,582Direct
Mar 13, 2023Common StockSSaleDisposed−5,324$44.97F7−$239,420.28258Direct
Mar 13, 2023Common StockSSaleDisposed−258$44.14F8−$11,388.120Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 10, 2023Common StockMOption exerciseDisposed−5,582$0.00$011,164Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.86 to $43.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.12 to $42.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F5

Restricted stock units convert into common stock on a one-for-one basis.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.58 to $45.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.82 to $44.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)